Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...
Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim ...
Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
Researchers from the European Molecular Biology Laboratory have found that dextromethorphan, a common cough syrup ingredient, ...
The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...
The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...
Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.
“The positive FIBRONEER™-ILD topline result shows the potential of nerandomilast in progressive pulmonary fibrosis. The hope is that the safety and tolerability profile we are initially seeing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback